ArticleFrontiers in oncology2025
Predictors of postoperative recurrence in locally advanced gastric cancer patients achieving pathological complete response after neoadjuvant therapy: a matched case-control study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Achieving a pathological complete response (pCR) after neoadjuvant therapy is a favorable prognostic factor in locally advanced gastric/gastroesophageal junction cancer. However, recurrence still occurs in a subset of these patients. This study aimed to identify clinical factors associated with recurrence in patients who attained pCR. Methods: This retrospective study included 16 patients with recurrence early after achieving pCR. Each case was matched with two controls (non-recurrence) based on age and sex. Clinical characteristics were compared, and factors with Results: Univariate analysis identified significant differences between recurrence and non-recurrence groups in tumor grade, neoadjuvant therapy regimen, PD-L1 expression, and preoperative CEA levels. Multivariate analysis established clinical T stage and neoadjuvant regimen as independent prognostic factors for recurrence. Specifically, compared to patients with cT4 stage and those receiving neoadjuvant chemotherapy, patients with cT3 stage (P=0.035) and those receiving neoadjuvant chemoimmunotherapy (P=0.009) had a significantly lower risk of recurrence. Conclusion: Achieving pCR does not guarantee cure. Clinical T stage and neoadjuvant regimen were independent risk factors for recurrence. Identifying high-risk patients among those with pCR was crucial for tailoring personalized surveillance and adjuvant strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.